Baxter (NYSE:BAX) agreed to offload its commercial vaccines business to pharmaceutical rival Pfizer (NYSE:PFE) for $635 million in cash.
Baxter
Baxter reports Q2 sales jump, narrows earnings guidance
JenaValve taps ex-AtriCure chief Drachman for CEO | Personnel Moves
Conor MedSystems can’t slip $100 million breach of contract lawsuit | Medtech legal news for the week of May 26, 2014
Supreme Court declines review of Baxter/Fresenius patent row
Press Release: Baxter Receives 510(k) Clearance for Next-Generation SIGMA Spectrum Infusion Pump with Master Drug Library
Baxter lands FDA nod for next-gen Sigma Spectrum infusion pump
Baxter pump recall gets FDA’s highest-risk label following 9 severe injuries
Former Stryker marketing executive escapes jail sentence | Medtech Wall Street news for the week of Apr. 21, 2014
Baxter blows away Wall Street as renal sales surge in Q1
Baxter adds 30 jobs in Malta | Medtech personnel moves for the week of Apr. 7, 2014
Report: Baxter to add 30 jobs in Malta
April 2, 2014 by Arezu Sarvestani
Malta regulators announced this week that healthcare titan Baxter plans to add 30 additional jobs in the country.